The putative "silent" 5-HT1A receptor antagonist, WAY 100635, has inverse agonist properties at cloned human 5-HT1A receptors

被引:32
|
作者
Cosi, C [1 ]
Koek, W [1 ]
机构
[1] Ctr Rech Pierre Fabre, Div Neurobiol 2, F-80106 Castres, France
关键词
S-35]GTP gamma S binding; 5-HT1A receptor; inverse agonist; WAY; 100635;
D O I
10.1016/S0014-2999(00)00410-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Agonist binding to G protein-coupled receptors induces the formation of a receptor-G protein complex and subsequent guanosine 5'-diphosphate/guanosine 5'-triphosphate (GDP/GTP) exchange. Some receptors, however, form receptor-a protein complexes and promote GDP/GTP exchange even when not occupied by agonists. Such receptors preferentially activate pertussis toxin-sensitive G proteins (i.e., G(i)/G(o)), and the interactions of receptors and G proteins are affected by monovalent cations (most notably Na+), both in the occupied and unoccupied state. We investigated the effects of Na+ on the intrinsic activity of 5-hydroxytryptamine,. (5-HT1A) receptor ligands, measured as maximal effect (E-MAX), using guanosine 5'-0-(3-[S-35]thio)-triphosphate ([S-35]GTP gamma S) binding to membranes prepared from human epithelioid carcinoma (HeLa) cells, expressing 500 fmol/mg protein of cloned human 5-HT1A receptor (HA7 cells). A decrease of the NaCl concentration decreased the maximal effect of serotonin, increased basal [S-35]GTP gamma S binding, and increased the negative intrinsic activity of spiperone and N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]-N-(2-pyridinyl)cyclohexanecarboxamide (WAY 100635). This ability of WAY 100635 to decrease basal [S-35]GTP gamma S binding was antagonized by (s)-N-tert-butyl-3-(4-(2-methaxyphenyl)piperazine-1-yl)-2-phenylpropanamide ((s)-WAY 100135) (pA(2) = 7.77). Further, WAY 100635 was able to antagonize carboxamidotryptamine (5-CT)-stimulated [S-35]GTP gamma S binding with a pA(2) of 9.9, in standard NaCl conditions, and of 9.7, in the absence of NaCl. Changes in membrane concentration did not affect the ability of WAY 100635 to decrease [S-35]GTP gamma S binding. WAY 100635 did not affect basal [S-35]GTP gamma S binding to membranes from untransfected HeLa cells. Pertussis toxin (200 ng/ml) prevented WAY 100635 and spiperone to decrease [S-35]GTP gamma S binding, showing that their effects were mediated by G proteins of the G(i)/G(o) family. In conclusion, the constitutive and stimulated activity of human 5-HT1A receptors expressed in HA7 cells is sodium-dependent, which allowed to confirm the 5-HT1A inverse agonist properties of spiperone, and to show that WAY 100635 is an inverse agonist at 5-HT1A receptors that inhibits basal [S-35]GTP gamma S binding to a lesser extent than spiperone. [S-35]GTP gamma S binding to membranes from HA7 cells under low NaCl conditions appears to be especially suitable to evidence and pharmacologically analyze the inverse agonist properties of 5-HT1A receptor ligands. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:9 / 15
页数:7
相关论文
共 50 条
  • [21] WAY-100635, an antagonist of 5-HT1A receptor, causes malformations of the CNS in ascidian embryos
    Pennati, R
    Groppelli, S
    Sotgia, C
    Zega, G
    Pestarino, M
    De Bernardi, F
    DEVELOPMENT GENES AND EVOLUTION, 2003, 213 (04) : 187 - 192
  • [22] Facilitatory effects of WAY-100635, a 5-HT1A receptor antagonist, on lordosis in female rats
    Kishitake, M
    Yamanouchi, K
    NEUROSCIENCE LETTERS, 2004, 371 (2-3) : 147 - 151
  • [23] On the elevated plus-maze the anxiolytic-like effects of the 5-HT1A agonist, 8-OH-DPAT, but not the anxiogenic-like effects of the 5-HT1A partial agonist, buspirone, are blocked by the 5-HT1A antagonist, WAY 100635
    N. Collinson
    G. R. Dawson
    Psychopharmacology, 1997, 132 : 35 - 43
  • [24] Separate and combined effects of fluoxetine and a 5-HT1A receptor agonist or antagonist on 5-HT1A and 5-HT1B autoreceptor activity in the rat brain
    Shalom, G
    Gur, E
    Van de Kar, LD
    Lerer, B
    Newman, ME
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S15 - S16
  • [25] Effects of 5-HT1A Receptor Antagonist and 5-HT2A Receptor Agonist on Morphine Withdrawal
    Ramezani, Mahdi
    Shahidi, Siamak
    Afshar, Simin
    Habibi, Parisa
    Hashemi-Firouzi, Nasrin
    NEUROCHEMICAL JOURNAL, 2024, 18 (02) : 321 - 330
  • [26] Preferential in vivo action of F15599, a novel 5-HT1A receptor agonist, at postsynaptic 5-HT1A receptors
    Llado-Pelfort, L.
    Assie, M-B
    Newman-Tancredi, A.
    Artigas, F.
    Celada, P.
    BRITISH JOURNAL OF PHARMACOLOGY, 2010, 160 (08) : 1929 - 1940
  • [27] 5-HT1A receptor agonist affects fear conditioning through stimulations of the postsynaptic 5-HT1A receptors in the hippocampus and amygdala
    Li, XB
    Inoue, T
    Abekawa, T
    Weng, SM
    Nakagawa, S
    Izumi, T
    Koyama, T
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 532 (1-2) : 74 - 80
  • [28] The 5-HT1A receptor antagonist p-MPPI blocks responses mediated by postsynaptic and presynaptic 5-HT1A receptors
    Allen, AR
    Singh, A
    Zhuang, ZP
    Kung, MP
    Kung, HF
    Lucki, I
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1997, 57 (1-2) : 301 - 307
  • [29] WAY 100635, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by blockade of hippocampal NMDA receptors
    Carli, M
    Silva, S
    Balducci, C
    Samanin, R
    NEUROPHARMACOLOGY, 1999, 38 (08) : 1165 - 1173
  • [30] A 5-HT-evoked depolarisation is revealed by the 5-HT1A antagonist way-100635 in the rat DRN.
    Robinson, SM
    Larkman, PM
    Kelly, JS
    EUROPEAN JOURNAL OF NEUROSCIENCE, 1998, 10 : 348 - 348